Pharmaceutical Industry

Merck signs $356-million U.S. supply deal for experimental COVID-19 treatment

Canopy Growth cuts ties with investment company Canopy Rivers

Newly approved treatment could save a young child in Edmonton with a rare disease. It costs $2.8-million per dose

Merck sells stake in vaccine developer Moderna

Ottawa blocks Trump plan to allow bulk U.S. import of cheaper prescription drugs from Canada

The credibility of pharmaceutical companies is on the line. Will they get it right?

Trump makes late-term bid to lower prescription drug costs

Pharmaceutical industry offers Ottawa $1-billion to scrap pending drug pricing rules, documents show

Developing a coronavirus vaccine is just the first step – distribution presents a whole new challenge

Cardinal Health and AmerisourceBergen book billions in costs related to opioid lawsuits

McKesson says cost of opioid settlements could reach $21-billion

Britain starts accelerated review for AstraZeneca’s potential COVID-19 vaccine

U.S. to charge Teva with conspiring to raise prices of generic drugs, sources say

Johnson & Johnson buying Momenta Pharmaceuticals for around $6.5-billion

U.S. states reportedly seeking $26.4-billion from drug firms in opioid litigation

Chairman of China’s Sinopharm rules out high price for potential coronavirus vaccine

Sanofi snags another U.S. biotech firm with $3.7-billion Principia deal